Neurohypophyseal Hormones, Analogs, and Fragments: Their Effect on Puromycin-induced Amnesia

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1975 Oct 1

PMID 1060098

Citations 8

Authors

R Walter

P L Hoffman

J B FLEXNER

L B FLEXNER

Affiliations

Soon will be listed here.

Abstract

Neurohypophyseal hormones and several of their analogs, as well as N-terminal and C-terminal fragments, have been studied for their ability to attenuate puromycin-induced amnesia in mice. [8-Lysine]vasopressin, [8-arginine]vasopressin, and the analogs des-9-glycinamide-[8-lysine]vasopressin, [1-beta-mercaptopropionic acid, 8-lysine]vasopressin, [1,6-aminosuberic acid, 8-lysine]vasopressin, [4-leucine, 8-lysine]vasopressin, glycyl-glycyl-glycyl-[8-lysine]vasopressin, [1-beta-mercaptopropionic acid, 8-D-arginine]vasopressin, and [1,6-aminosuberic acid, 8-arginine]vasopressin are active. [8-Arginine]oxytocin as well as oxytocin and all of its other analogs tested are inactive with the striking exception of glycyl-glycyl-glycyl-oxytocin. The structural aspects of the neurohypophyseal hormones which appear to be important for significant activity in memory consolidation include the combination of a cyclic moiety containing the Tyr and Phe residues along with a basic residue in position 8. Another series of active compounds comprises C-terminal neurohypophyseal peptides and analogs thereof, including the naturally occurring Pro-Leu-Gly-NH2 and, most surprisingly, Leu-Gly-NH2, as well as its derivatives D-Leu-Gly-NH2 and the diketopiperazine, cyclo(-Leu-Gly-).

Citing Articles

Vasopressin and alcohol: a multifaceted relationship.

Harper K, Knapp D, Criswell H, Breese G Psychopharmacology (Berl). 2018; 235(12):3363-3379.

PMID: 30392132 PMC: 6286152. DOI: 10.1007/s00213-018-5099-x.

Concepts for biologically active peptides.

Kastin A, Pan W Curr Pharm Des. 2010; 16(30):3390-400.

PMID: 20726835 PMC: 3535498. DOI: 10.2174/138161210793563491.

Two classes of arginine vasopressin binding sites on rat brain membranes.

Junig J, Abood L, Skrobala A Neurochem Res. 1985; 10(9):1187-202.

PMID: 4058655 DOI: 10.1007/BF00964839.

Immunocytochemistry of magnocellular neurons of supraoptic and paraventricular nuclei of normal and Brattleboro rats with vasopressin anti-idiotype antibody.

Knigge K, Piekut D, Berlove D Cell Tissue Res. 1986; 246(3):509-13.

PMID: 2947686 DOI: 10.1007/BF00215190.

Neuropeptides: animal behaviour and human psychopathology.

de Wied D, van Ree J Eur Arch Psychiatry Neurol Sci. 1989; 238(5-6):323-31.

PMID: 2670577 DOI: 10.1007/BF00449813.

References

MUNSICK R . Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormones and analogues. Endocrinology. 1960; 6:451-7. DOI: 10.1210/endo-66-3-451. View

AROSKAR J, Chan W, STOUFFER J, Schneider C, MURTI V, DUVIGNEAUD V . RENAL EXCRETION AND TISSUE DISTRIBUTION OF RADIOACTIVITY AFTER ADMINISTRATION OF TRITIUM-LABELED OXYTOCIN TO RATS. Endocrinology. 1964; 74:226-32. DOI: 10.1210/endo-74-2-226. View

KIMBROUGH Jr R, CASH W, Branda L, Chan W, DU VIGNEAUD V . Synthesis and biological properties of 1-desamino-8-lysine-vasopressin. J Biol Chem. 1963; 238:1411-4. View

Sawyer W . Differences in the antidiuretic responses of rats to the intravenous administration of lysine and arginine vasopressins. Endocrinology. 1958; 63(5):694-8. DOI: 10.1210/endo-63-5-694. View

Kyncl J, Rezabek K, Kasafirek E, Pliska V, Rudinger J . 'Hormonogen' analogues of lysine vasopressin: rat pressor and antidiuretic activities. Eur J Pharmacol. 1974; 28(2):294-301. DOI: 10.1016/0014-2999(74)90282-9. View

King A, de Wied D . Localized behavioral effects of vasopressin on maintenance of an active avoidance response in rats. J Comp Physiol Psychol. 1974; 86(6):1008-18. DOI: 10.1037/h0037636. View

Brewster A, Glasel J, Hruby V . Conformational studies on tocinamide and deaminotocinamide by 220 MHz nuclear magnetic resonance spectroscopy. Proc Natl Acad Sci U S A. 1972; 69(6):1470-4. PMC: 426728. DOI: 10.1073/pnas.69.6.1470. View

Walter R, Glickson J, SCHWARTZ I, Havran R, Meienhofer J, Urry D . Conformation of lysine vasopressin: a comparison with oxytocin. Proc Natl Acad Sci U S A. 1972; 69(7):1920-4. PMC: 426832. DOI: 10.1073/pnas.69.7.1920. View

Von Dreele P, Brewster A, BOVEY F, Scheraga H, FERGER M, DU VIGNEAUD V . Nuclear magnetic resonance studies of lysine-vasopressin: structural constraints. Proc Natl Acad Sci U S A. 1971; 68(12):3088-91. PMC: 389596. DOI: 10.1073/pnas.68.12.3088. View

10.

Celis M, Taleisnik S, Walter R . Regulation of formation and proposed structure of the factor inhibiting the release of melanocyte-stimulating hormone. Proc Natl Acad Sci U S A. 1971; 68(7):1428-33. PMC: 389210. DOI: 10.1073/pnas.68.7.1428. View

11.

Capra J, Cheng K, Friesen H, North W, Walter R . Evolution of neurophysin proteins: the partial sequence of human neurophysin-I. FEBS Lett. 1974; 46(1):71-4. DOI: 10.1016/0014-5793(74)80337-6. View

12.

Takahashi T, Konishi S, Powell D, Leeman S, Otsuka M . Identification of the motoneuron-depolarizing peptide in bovine dorsal root as hypothalamic substance P. Brain Res. 1974; 73(1):59-69. DOI: 10.1016/0006-8993(74)91007-5. View

13.

Plotnikoff N, Kastin A . Oxotremorine antagonism by prolyl-leucyl-glycine-amide administered by different routes and with several anticholinergics. Pharmacol Biochem Behav. 1974; 2(3):417-9. DOI: 10.1016/0091-3057(74)90090-2. View

14.

Kastin A, Dempsey G, LeBlanc B, DYSTER-AAS K, Schally A . Extinction of an appetitive operant response after administration of MSH. Horm Behav. 1974; 5(2):135-9. DOI: 10.1016/0018-506x(74)90037-3. View

15.

Dyckes D, FERGER M, DU VIGNEAUD V, Chan W . Synthesis and some of the pharmacological properties of (4-leucine)-8-lysine-vasopressin and (1-deamino,4-leucine)-8-lysine-vasopressin. J Med Chem. 1973; 16(7):843-7. DOI: 10.1021/jm00265a022. View

16.

Havran R . Solid-phase synthesis of lysine vasopressin analogs: (1-beta-mercaptopropionic acid, 8-lysine)-vasopression and (1-beta-mercaptopropionic acid, 8-(epsilon-N-p-toluenesulfonyl)-lysine)-vasopressin. Experientia. 1973; 29(5):520-1. DOI: 10.1007/BF01926638. View

17.

Redding T, Kastin A, Nair R, Schally A . Distribution, half-life, and excretion of 14 C- and 3 H-labeled L-prolyl-L-leucyl-glycinamide in the rat. Neuroendocrinology. 1973; 11(2):92-100. DOI: 10.1159/000122121. View

18.

Bohus B, Ader R, de Wied D . Effects of vasopressin on active and passive avoidance behavior. Horm Behav. 1972; 3(3):191-7. DOI: 10.1016/0018-506x(72)90031-1. View

19.

Kastin A, Barbeau A . Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease. Can Med Assoc J. 1972; 107(11):1079-81. PMC: 1941054. View

20.

Wang S . Synthesis of desglycinamide lysine vasopressin and its behavioral activity in rats. Biochem Biophys Res Commun. 1972; 48(6):1511-5. DOI: 10.1016/0006-291x(72)90885-6. View